Laboratory Detection of Human Retroviral Infection

AIDS and Other Manifestations of HIV Infection

Volumn , Issue , 2004, Pages 147-183

  Weiss, Stanley H ^a   Cowan, Elliot P ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70449398576     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012764051-8/50010-X     Document Type: Chapter

References (431)

1. Gallo RC, Salahuddin SZ, Popovic M, Shearer GM, Kaplan M, Haynes BF, et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 1984, 224:500-503.
2. Popovic M, Sarngadharan MG, Read E, Gallo RC Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and Pre-AIDS. Science 1984, 224:497-500.
3. Landesman SH, Ginzburg HM, Weiss SH The AIDS epidemic. N Engl J Med 1985, 312:521-525.
4. Blattner WA Blattner and colleagues respond to Duesberg. Science 1988, 241:514-517.
5. Weiss SH, Biggar RJ The epidemiology of human retrovirus-associated illnesses. Mt Sinai J Med 1986, 53:579-591.
6. Melbye M The natural history of human T lymphotropic virus-III infection: the cause of AIDS. Brit Med J 1986, 292:5-12.
7. Blattner WA, Reitz MS, Colclough G, Weiss SH HIV/AIDS in laboratory workers infected with HTLV-IIIB. IXth International Conference on AIDS 1993, I:281.
8. Hardy WDJ Feline oncoretroviruses. The retroviridae 1994, 2:109-169. Plenum, New York. J.A. Levy (Ed.).
9. Coffin J, Haase A, Levy JA, Montagnier L, Oroszlan S, Teich N, et al. Human immunodeficiency virus. Science 1986, 232:697.
10. Barre-Sinoussi F, Chermann J-C, Rey F, Nugeyre MT, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
11. Hahn BH, Shaw GM, Taylor ME, Redfield RR, Markham PD, Salahuddin SZ, et al. Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 1986, 232:1548-1553.
12. Saag MS, Hahn BH, Gibbons J, Li Y, Parks ES, Parks WP, et al. Extensive variation of human immunodeficiency virus type 1 in vivo. Nature 1988, 334:440-444.
13. Wain-Hobson S HIV genome variability in vivo. AIDS 1989, 3(Suppl. 1):S13-S18.
14. Loussert-Ajaka I, Ly TD, Chaix ML, Ingrand D, Saragosti S, Couroucé A-M, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994, 343:1393-1394.
15. Brun-Vezinet F, Katlama C, Ceuninck D, Andrade D, Dario D, Rey MA, et al. Lymphadenopathy associated virus type 2 (LAV-2) - seroepidemiological study in Cape Verde islands. 3rd International Conference on AIDS 1987, 211.
16. Kanki P, M'Boup S, Barin F, Ricard D, Denis F, Essex M, et al. HTLV-IV and HTLV-III/HIV in West Africa. 3rd International Conference on AIDS 1987, 211.
17. Descamps D, Collin G, Loussert-Ajaka I, Saragosti S, Simon F, Brun-Vezinet F HIV-1 group O sensitivity to antiretroviral drugs. AIDS 1996, 9(8):977-978.
18. Blattner WA Epidemiology of HTLV-I and associated diseases. Human Retrovirology: HTLV 1990, 251-265. Raven Press, New York. W.A. Blattner (Ed.).
19. Dodd RY Donor screening and epidemiology. Prog Clin Biol Res 1985, 182:389-405.
20. Farzadegan H, Polis MA, Wolinsky SM, Rinaldo CR, Sninsky JJ, Kwok S, et al. Loss of human immunodeficiency virus type 1 (HIV-1) antibodies with evidence of viral infection in asymptomatic homosexual men. Ann Intern Med 1988, 108:785-790.
21. CDC Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR 1987, 36:225-235.
22. Carlson JR, Bryant ML, Hinrichs SH, Yamamoto JK, Levy NB, Yee J-A, et al. AIDS serology testing in low- and high-risk groups. JAMA 1985, 253:3405-3408.
23. Weiss SH, Goedert JJ, Sarngadharan MG, Bodner AJ, Gallo RC, et al. Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA 1985, 253:221-225. AIDS Seroepidemiology Collaborative Working Group.
24. Weiss SH, Goedert JJ Screening for HTLV-III antibodies: the relation between prevalence and positive predictive value and its social consequences. JAMA 1985, 253:3397.
25. CDC Revised guidelines for HIV counseling, testing and referral. MMWR 2001, 50(RR-19):1-57.
26. CDC Notice to readers. Approval of a new rapid test for HIV antibody. MMWR 2002, 51(46):1051-1052.
27. CDC Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001, 50(RR-11):i-ii.
28. CDC Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001, 50(RR-11):1-54.
29. Schalla WO, Schulte JM, Francis DP, Hofherr LK, Peddecord KM, Heam TL, et al. Guidelines for laboratory test result reporting of human immunodeficiency virus type 1 ribonucleic acid determination. MMWR 2001, 50(RR-20):1-12. Recommendations from a CDC Working Group.
30. CDC Revised recommendations for HIV screening of pregnant women. MMWR 2001, 50(RR-19):59-85.
31. Saxinger WC, Gallo RC Application of the indirect enzyme-linked immunosorbent assay microtest to the detection and surveillance of human T-cell leukemia-lymphoma virus. Lab Invest 1983, 49:371-377.
32. Sarngadharan MG, Popovic M, Bruch L, Schupbach J, Gallo RC Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science 1984, 224:506-508.
33. Schupbach J, Popovic M, Gilden RV, Gonda MA, Sarngadharan MG, Gallo RC Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science 1984, 224:503-505.
34. CDC Additional recommendations to reduce sexual and drug abuse-related transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus. MMWR 1986, 35:152-155.
35. CDC Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR 1999, 48:1-28.
36. Marlink RG, Allan JS, McLane MF, Essex M, Anderson KC, Groopman JE Low sensitivity of ELISA testing in early HIV infection. N Engl J Med 1986, 315:1549.
37. Salahuddin SZ, Groopman JE, Markham PD, Sarngadharan MG, Redfield RR, McLane MF, et al. HTLV-III in symptom-free seronegative persons. Lancet 1984, ii:1418-1420.
38. Marwick C Use of AIDS antibody test may provide more answers. JAMA 1985, 253:1694-1699.
39. Sivak SL, Wormser GP Predictive value of a screening test for antibodies to HTLV-III. Am J Clin Pathol 1986, 85:700-703.
40. Petricciani JC, Seto B, Wells M, Quinnan G, McDougal JS, Bodner AJ An analysis of serum samples positive for HTLV-III antibodies. N Engl J Med 1985, 313:47-48.
41. CDC Results of human T-lymphotropic virus type III test kits reported from blood collection centers - United States, April 22-May 19, 1985. MMWR 1985, 34:375-376.
42. CDC Notice to Readers: Potential shortage of supplemental test kits for detecting HIV-1 antibodies. MMWR 2002, 51:395-396.
43. CDC Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR 1989, 38(S-7):1-7.
44. Gallo D, George JR, Fitchen JH, Goldstein AS, Hindahl M Evaluation of a system using oral mucosal transudate for HIV-1 antibody screening and confirmatory testing. JAMA 1997, 277(3):254-258. The OraSure HIV Clinical Trials Group.
45. The Consortium for Retrovirus Serology Serological diagnosis of human immunodeficiency virus infection by Western blot testing. JAMA 1988, 260:674-679.
46. Dodd RYFC The western immunoblot procedure for HIV antibodies and its interpretation. Arch Pathol Lab Med 1990, 114:240-245.
47. Sullivan PT, Mucke H Evaluation of an indirect immunofluoresence assay for confirmation of human immunodeficiency virus type 1 antibody in U.S. blood donor sera. J Clin Micro 1992, 30:2509-2510.
48. Iltis JP, Patel NM, Lee SR, Barmat SL, Wallen WC Comparative evaluation of an immunofluorescent antibody test, enzyme immunoassay, and western blot for the detection of HIV-1 antibody. Intervirology 1990, 31:122-128.
49. Stramer SL, Sapan CV, Henderson SE, et al. Commercial HIV-immunofluorescence assay (IFA) in confirmatory algorithms for HIV-1/2 EIA. Meeting of the International Society of Blood Transfusion 1994, Amsterdam, The Netherlands.
50. Cordeiro ML, Turpin CS, McAdams SA A comparative study of saliva and OraSure oral fluid. Ann NY Acad Sci 1993, 694:330-331.
51. Granade TC, Phillips SK, Parekh B, et al. Detection of antibodies to human immunodeficiency virus type 1 in oral fluids: a largescale evaluation of immunoassay performance. Clin Diag Lab Immunol 1998, 5:171-175.
52. Weiss SH, Mann DL, Murray C, Popovic M HLA-DR antibodies and HTLV-III antibody ELISA testing. Lancet 1985, ii:157.
53. Kühnl P, Seidl S, Holzberger G HLA DR4 antibodies cause positive HTLV-III antibody elisa results. Lancet 1985, i:1222-1223.
54. Hunter JB, Menitove JE HLA antibodies detected by ELISA HTLV-III antibody kits. Lancet 1985, ii:397.
55. Arthur LO, Bess JW, Heffner-Barrett C, Robey WG, Henderson LE, Fischinger PJ, et al. Removal of HLA DR antigens from HTLV-III preparations using immunoaffinity chromatography. J Cell Biochem 1986, 10A:226. (Suppl.).
56. Chang TW, Kato I, McKinney S, Chanda P, Barone AD, Wong-Staal F, et al. Detection of antibodies to human T-cell lymphotropic virus-III (HTLV-III) with an immunoassay employing a recombinant Escherichia coli-derived viral antigenic peptide. Biotechnology 1985, 3:905-909.
57. Cao Y, Friedman-Kien AE, Chuba JV, Mirabile M, Hosein B IgG antibodies to HIV-1 in urine of HIV-1 seropositive individuals. Lancet 1988, i:831-832.
58. Connell JA, Parry JV, Mortimer PP, Duncan RJS, McLean KA, Johnson AM, et al. Preliminary report: Accurate assays for anti-HIV in urine. Lancet 1990, 335:1366-1369.
59. Desai S, Bates H, Michalski FJ Detection of antibody to HIV-1 urine. Lancet 1991, 337:183-184.
60. Reagan KJ, Lile CC, Book GW, Devash Y, Winslow DL, Bincsik A Use of urine for HIV-1 antibody screening. Lancet 1991, 335:358-359.
61. Bauer G, Johnson J, Lewis G, Gottfried T, Urnovitz H, Cole G Antibodies to HIV-1 in urine of children of HIV-1-infected women. Lancet 1992, 340:559.
62. Lim WL, Cheng KC Antibody-capture particle-adherence test for antibody to HIV-1 in urine. Lancet 1992, 340:1161.
63. Cao Y, Hosein B, Borkowsky W, Mirabile M, Baker L, Baldwin D, et al. Antibodies to human immunodeficiency virus type 1 in the urine specimens of HIV-1 seropositive individuals. AIDS Res Hum Retroviruses 1989, 5:311-319.
64. Brignoli E, Pages J, Dalbon P, Jolivet M, Vernet G Detection of antibodies to HIV in urine samples from HIV infected people using a modified automated test (VIDAS). IXth International Conference on AIDS 1993, I:541.
65. Li JJ, Huang YQ, Poiesz BJ, Zaumetzger-Abbot L, Friedman-Kien AE Detection of human immunodeficiency virus type 1 (HIV-1) in urine cell pellets from HIV-1-seropositive individuals. J Clin Microbiol 1992, 30:1051-1055.
66. Hashida S, Hirota K, Hashinaka K, Saitoh A, Nakata A, Shinagawa H, et al. Detection of antibody IgG to HIV-1 in urine by sensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) using recombinant proteins as antigens for diagnosis of HIV-1 infection. J Clin Lab Anal 1993, 7:353-364.
67. Urnovitz HB, Clerici M, Shearer GM, Gottfried TD, Robison DJ, Lutwick LI, et al. HIV-1 antibody serum negativity with urine positivity. Lancet 1993, 342:1458-1459.
68. McCarthy M No-needle HIV test approved by FDA. Lancet 1996, 347(9016):1683.
69. Shoeman RL, Pottathil R, Metroka C Antibodies to HIV in saliva. N Engl J Med 1989, 320:1145-1146.
70. Archibald DW, Cole GA In vitro inhibition of HIV-1 infectivity by human salivas. AIDS Res Hum Retroviruses 1990, 6:1425-1432.
71. Major CJ, Read SE, Coates RA, Francis A, McLaughlin BJ, Millson M, et al. Comparison of saliva and blood for human immunodeficiency virus prevalence testing. J Infect Dis 1991, 163:699-702.
72. Morris DF False positive salivary HIV test. Brit Med J 1992, 305:834.
73. Fitzgibbons D, Barriga G, Seymour E, Stramer S HIV antibody EIA and Western blot assay results on paired serum and saliva specimens. Ann NY Acad Sci 1993, 694:314-316.
74. CDC Update: serologic testing for antibody to human immunodeficiency virus. MMWR 1988, 36:833-840.
75. Carlson JR, Mertens SC, Yee JL, Gardner MB, Watson-Williams EJ, Ghrayeb J, et al. Preliminary communication: rapid, easy and economical screening test for antibodies to the human immunodeficiency virus. Lancet 1987, i:361-362.
76. Weiss SH, Lombardo J, Michaels J, Sharer LR, Tayyarah M, Leonard J, et al. AIDS due to HIV-2 infection - New Jersey. MMWR 1988, 37:33-35.
77. Kloser PC, Mangia AJ, Leonard J, Lombardo JM, Michaels J, Denny TN, et al. HIV-2-associated AIDS in the United States. The first case. Arch Intern Med 1989, 149:1875-1877.
78. Lombardo JM, Horsburgh CR, Denny TN, Michaels J, Schable C, Meyenhofer MF, et al. Evaluation of an atypical HIV type 1 antibody: serological pattern leading to detection of HIV type 2 infection in North America. Arch Pathol Lab Med 1989, 113:1245-1249.
79. Abiola PO, Parry JV, Mortimer PP Sensitivity for anti-HIV-2 of combined HIV antibody kits. Lancet 1990, 336:1386-1387.
80. Myrmel H, Holm-Hansen C, Haukenes G Evaluation of two rapid tests for the detection of HIV-1/HIV-2 antibodies. AIDS 1990, 4:1164-1166.
81. Das PC, Smit Sibinga CT Combined HIV-1/2 assay kits. Lancet 1991, 337:125-126.
82. CDC Update: HIV-2 infection-United States. MMWR 1989, 108:785-790.
83. Marquart K-H, Muller HAG Different serological HIV-2 results in three HIV-1-infected men from the Gambia. Infection 1989, 17:63-64.
84. Pieniazek D, Peralta JM, Ferreira JA, Krebs JW, Owen SM, Sion FS, et al. Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain reaction. AIDS 1991, 5:1293-1299.
85. Busch MP The need for rigorous molecular epidemiology. AIDS 1991, 5:1379-1380.
86. Simon F, Meana A, Rinaldi R, Ancelle-Park RM, Dazza MC, Pepin JM, et al. HIV-1 competitive ELISA for serological diagnosis of HIV-2 positivity. AIDS 1990, 4:1169-1170.
87. Parekh BS, Pau C-P, Granade TC, Rayfield M, De Cock KM, Gayle H, et al. Oligomeric nature of transmembrane glycoproteins of HIV-2: procedures for their efficient dissociation and preparation of western blots for diagnosis. AIDS 1991, 5:1009-1013.
88. Schulz TF, Oberhuber W, Schmidt B, Gschnait F, Hengster P, Wachter H, et al. Serological discrimination between HIV-1 and HIV-2. Lancet 1988, ii:162-163.
89. Holzer TJ, Allen RG, Heynen CA, Kennedy MM, Knigge MF, Paul DA, et al. Discrimination of HIV-2 infection from HIV-1 infection by Western blot and radioimmunoprecipitation assay. AIDS Res Hum Retroviruses 1990, 6:515-524.
90. Grankvist O, Bredberg-Raden U, Gustafsson A, Albert J, Albino P, Andreasson PA, et al. Improved detection of HIV-2 DNA in clinical samples using a nested primer-based polymerase chain reaction. J Acquir Immune Defic Syndr Hum Retrovirol 1992, 5:286-293.
91. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. (erratum appears in JAMA 1999 May 26;281(20): 1893.). JAMA 1998, 280(1):42-48.
92. Machado DM, Delwart EL, Diaz RS, de Oliveira CF, Alves K, Rawal BD, et al. Use of the sensitive/less-sensitive (detuned) EIA strategy for targeting genetic analysis of HIV-1 to recently infected blood donors. AIDS 2002, 16(1):113-119.
93. Jong JD, Simon F, Van der Groen G, Baan E, Saragosti S, Brun-Vezinet F, et al. V3 loop sequence analysis of seven HIV type 1 group O isolates phenotyped in peripheral blood mononuclear cells and MT-2 cells. AIDS Res Hum Retroviruses 1996, 12(16):1503-1507.
94. Shable C, Zekeng L, Pau C-P Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994, 344:1333-1334.
95. CDC Persistent lack of detectable HIV-1 antibody in a person with HIV infection - Utah, 1995. MMWR 1996, 45(9):181-185.
96. Knüver-Hopf J, Heinze H, Lambrecht B, Mohr H, Beyer J, Schmitt H Blood donations indeterminate in HIV-1 Western blot analysed by IgM immunoblot and polymerase chain reaction. Vox Sang 1993, 64:89-93.
97. DiMarzo-Veronese F, Copeland TD, DeVico AL, Rahman R, Oroszlan S, Gallo RC, et al. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 1986, 231:1289-1291.
98. Wright CM, Felber BK, Paskalis H, Pavlakis GN Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science 1986, 234:988-992.
99. DiMarzo-Veronese F, Samgadharan MG, Rahman R, Markham PD, Popovic M, Bodner AJ, et al. Monoclonal antibodies specific for p24, the major core protein of human T-cell leukemia virus type III. Proc Natl Acad Sci USA 1985, 82:5199-5202.
100. Pieniazek D, Janini ML, Ramos A, Bandea C, Soriano V, Downing R, et al. Mixed infections with HIV-1 strains of different phylogenetic subtypes: implications for the evolution of the HIV/AIDS pandemic. Program and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections 1996, 148. Jan.28-Feb.2.
101. Robey WG, Safai B, Oroszlan S, Arthur LO, Gonda MA, Gallo RC, et al. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985, 228:593-595.
102. Barin F, McLane MF, Allan JS, Lee TH, Groopman JE, Essex M Virus envelope protein of HTLV-III represents the major target antigen for antibodies in AIDS patients. Science 1985, 228:1094-1096.
103. Allan JS, Coligan JE, Barin F, McLane MF, Sodroski JG, Rosen CA, et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985, 228:1091-1093.
104. CDC Update: serologic testing for HIV-1 antibody - United States, 1988 and 1989. MMWR 1990, 39:380-383.
105. Saag MS, Britz J Asymptomatic blood donor with a false positive HTLV-III western blot. N Engl J Med 1986, 314:118.
106. Carlson JR, Hinrichs SH, Levy NB, et al. Evaluation of commercial AIDS screening test kits. Lancet 1986, 1:1388.
107. Biggar RJ, Johnson BK, Musoke SS, Masembe JB, Silverstein DM, Warshow MM, et al. Severe illness associated with appearance of antibody to human immunodeficiency virus in an African. Brit Med J 1986, 293:1210-1211.
108. Mortimer PP The fallibility of HIV western blot. Lancet 1991, 337:286-287.
109. Esteban JI, Shih JW-K, Tai C-C, Bodner AJ, Kay JWD, Alter HJ Importance of western blot analysis in predicting infectivity of anti-HTLV-III/LAV positive blood. Lancet 1985, ii:1083-1086.
110. Ward JW, Grindon AJ, Feorino PM, Schable C, Parvin M, Allen JR Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. JAMA 1986, 256:357-361.
111. Imagawa DT, Lee MH, Wolinsky SM, Sano K, Morales F, Kwok S, et al. Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989, 320:1458-1462.
112. Wolinsky SM, Rinaldo CR, Kwok S, Sninsky JJ, Gupta P, Imagawa D, et al. Human immunodeficiency virus type 1 (HIV-1) infection a median of 18 months before a diagnostic western blot: evidence from a cohort of homosexual men. Ann Intern Med 1989, 111:961-972.
113. Mortimer J An alternative approach to confirming anti-HIV reactivity: A multi-country collaborative study. Bull WHO 1992, 70:751-756.
114. Weber B, Doerr HW Evaluation of the automated VIDAS system for the detection of anti-HIV-1 and anti-HIV-2 antibodies. J Virol Methods 1993, 42:63-74.
115. Pepin J, Dalby M, Gaye I, Berry N, Whittle H Long-term follow-up of subjects with an indeterminate HIV-2 western blot. AIDS 1991, 5:1274-1275.
116. Robert-Guroff M, Brown M, Gallo RC HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related-complex. Nature 1985, 316:72-74.
117. Weiss RA, Clapham PR, Cheingsong-Popov R, Dalgleish AG, Came CA, Weller IVD, et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985, 316:69-71.
118. Faulkner-Valle GP, De Rossi A, Gassa OD, Chieco-Bianchi L LAV/HTLV-III neutralizing antibodies in the sera of patients with AIDS, lymphadenopathy syndrome and asymptomatic seropositive individuals. Tumori 1986, 72:219-224.
119. Evans DJ, McKeating J, Meredith JM, Burke KL, Katrak K, John A, et al. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 1989, 339:385-388.
120. Wang CY, Looney DJ, Walfield AM, Ye J, Hosein B, Tam JP, et al. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991, 254:285-288.
121. Wiseman G, Rubinstein A, Martinez P, Lambert S, Devash Y, Goldstein H Cellular and antibody responses directed against the HIV-1 principal neutralizing domain in HIV-1-infected children. AIDS Res Hum Retroviruses 1991, 7:839-845.
122. Sarin PS, Sun DK, Thornton AH, Naylor PH, Goldstein AL Neutralization of HTLV-III/LAV replication by antiserum to thymosin-alpha-1. Science 1986, 232:1135-1137.
123. Goedert JJ, Drummond JE, Minkoff HL, Stevens R, Blattner WA, Mendez H, et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp 120. Lancet 1989, ii:1531-1534.
124. Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci USA 1990, 87:3445-3449.
125. Parekh BS, Shaffer N, Pau C-P, Abrams E, Thomas P, Pollack H, et al. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. AIDS 1991, 5:1179-1184.
126. Nara PL, Goudsmit J Sequence invariance and conformational dependence of the V3 region during the early emergence of HIV-1 neutralization escape mutants: a model of humoral V3-specific selection and deletion. Retroviruses of human A.I. D.S. and related animal diseases: quatrieme colloque des cent gardes 1989, 203-215. Pasteur Vaccins, Paris. M. Girard, L. Valette (Eds.).
127. Goudsmit J Genomic divergence within the coding sequence for the principal neutralization epitope of HIV-1. Retroviruses of human A.I. D.S. and related animal diseases: Quatrieme colloque des cent gardes 1989, 55-60. Pasteur Vaccins, Paris. M. Girard, L. Valette (Eds.).
128. Goudsmit J, Kuiken CL, Nara PL Linear versus conformational variation of V3 neutralization domains of HIV-1 during experimental and natural infection. AIDS 1989, 3:S119-S123.
129. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989, 86:6768-6772.
130. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990, 249:932-935.
131. LaRosa GJ, Weinhold K, Profy AT, Langlois AJ, Dreesman GR, Boswell RN, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant: further clarifications. Science 1991, 253:1146.
132. Ivanoff LA, Looney DJ, McDanal C, Morris JF, Wong-Staal F, Langlois AJ, et al. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res Hum Retroviruses 1991, 7:595-603.
133. Carrow EW, Vujcic LK, Glass WL, Seamon KB, Rastogi SC, Hendry RM, et al. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas. AIDS Res Hum Retroviruses 1991, 7:831-838.
134. Kodama T, Burns DPW, Silva DP, DiMarzo-Veronese F, Desrosiers RC Strain-specific neutralizing determinant in the transmembrane protein of simian immunodeficiency virus. J Virol 1991, 65:2010-2018.
135. Devash Y, Rusche JR, Nara PL Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain. Biotechnol Ther 1991, 2(1-2):49-62.
136. Golding B, Golding H, Preston S, Hernandez D, Beining PR, Manischewitz J, et al. Production of a novel antigen by conjugation of HIV-1 to Brucella abortus: studies of immunogenicity, isotype analysis, T-cell dependency, and syncytia inhibition. AIDS Res Hum Retroviruses 1991, 7:435-446.
137. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun N-C, et al. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991, 65:489-493.
138. Moore JP, Weiss RA Passive primate protection. Nature 1991, 352:376-377.
139. Zwart G, Landedijk H, van der Hoek L, de Jong J-J, Wolfs TFW, Ramautarsing C, et al. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 1991, 181:481-489.
140. Björling E, Scarlatti G, Von Gegerfelt A, Albert J, Biberfeld G, Chiodi F, et al. Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection. Virology 1993, 193:528-530.
141. Kaminsky LS, McHugh T, Stites D, Volberding P, Henle G, Henle W, et al. High prevalence of antibodies to AIDS-associated retrovirus in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci USA 1985, 82:5535-5539.
142. Chen J, Wang L, Chen JJY, Sahu GK, Tyring S, Ramsey K, et al. Detection of antibodies to human immunodeficiency virus (HIV) that recognize conformational epitopes of glycoproteins 160 and 41 often allows for early diagnosis of HIV infection. J Infect Dis 2002, 186:321-331.
143. Biggar RJ, Gigase PL, Melbye M, Kestens L, Sarin PS, Bodner AJ, et al. Elisa HTLV retrovirus antibody reactivity associated with malaria and immune complexes in healthy Africans. Lancet 1985, 2:520-523.
144. Blaser MJ, Cohn DL, Cody HJ, Penley KA, Judson FN, Saxinger WC, et al. Counterimmunoelectrophoresis for detection of human serum antibody to HTLV-III. J Immunol Methods 1986, 91:181-186.
145. Gazzolo L, Robert-Guroff M, Jennings A, Dodon MD, Najberg G, Peti M, et al. Type-I and type-III HTLV antibodies in hospitalized and out-patient Zairians. Int J Cancer 1985, 36:373-378.
146. Melbye M, Njelesani EK, Bayley A, Mukelabai K, Manuwele JK, Bowa FJ, et al. Evidence for heterosexual and clinical manifestations of human immunodeficiency virus infection and related conditions in Lusaka, Zambia. Lancet 1986, 2:1113-1115.
147. Saxinger WC, Levine P, Dean AG, de Thé G, Lange-Wantzin G, Moghissi J, et al. Evidence for exposure to HTLV-III in Uganda prior to 1973. Science 1985, 227:1036-1038.
148. Mann DL, DeSantis P, Mark G, Pfeifer A, Newman M, Gibbs N, et al. HTLV-I - associated B-cell CLL: indirect role for retrovirus in leukemogenesis. Science 1987, 236:1103-1106.
149. Sandler SG, Dodd RY, Fang CT Diagnostic tests for HIV infection. AIDS: etiology, diagnosis, treatment, and prevention 1988, 121-136. J.P.Lippincott, Philadelphia. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
150. Jackson JB, MacDonald KL, Cadwell J, Sullivan C, Kline WE, Hanson M, et al. Absence of HIV infection in blood donors with indeterminate western blot tests for antibody to HIV-1. N Engl J Med 1990, 322:217-222.
151. Celum CL, Coombs RW, Lafferty W, Inui TS, Louis PH, Gates CA, et al. Indeterminate human immunodeficiency virus type 1 western blots: seroconversion risk, specificity of supplemental tests, and an algorithm for evaluation. J Infect Dis 1991, 164:656-664.
152. Siegal FP, Lopez C, Hammer GS, Brown AE, Kornfeld SJ, Gold J, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med 1981, 305:1439-1444.
153. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981, 305:1425-1431.
154. Masur H, Michelis MA, Greene JB, Onorato I, Vande Stouwe RA, Holzman RS, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431-1438.
155. CDC Pneumocystis pneumonia - Los Angeles. MMWR 1981, 30:250-252.
156. CDC Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR 1981, 30:305-308.
157. CDC A cluster of Kaposi's sarcoma and Pneumocystis carinii pneumonia among homosexual male residents of Los Angeles and Orange countries, California. MMWR 1982, 31:305-307.
158. CDC Possible transfusion-associated acquired immune deficiency syndrome (AIDS) - California. MMWR 1982, 31:652-654.
159. Masur H, Michelis MA, Wormser GP, Lewin S, Gold J, Tapper ML, et al. Opportunistic infection in previously healthy women: initial manifestation of a community-acquired cellular immunodeficiency. Ann Intern Med 1982, 97:533-539.
160. Goedert JJ, Neuland CY, Wallen WC, Greene MH, Mann DL, Murray C, et al. Amyl nitrite may alter lymphocytes in homosexual men. Lancet 1982, i:412-416.
161. Eyster ME, Goedert JJ, Poon M-C, Preble OT Acid-labile alpha interferon: a possible preclinical marker for the acquired immunodeficiency syndrome in hemophilia. N Engl J Med 1983, 309:583-586.
162. Biggar RJ, Melbye M, Ebbesen P, Mann DL, Goedert JJ, Weinstock R, et al. Low T-lymphocyte ratios in homosexual men: epidemiologic evidence for a transmissible agent. JAMA 1984, 251:1441-1446.
163. Preble OT, Eyster ME, Goedert JJ Acid-labile alpha interferon. N Engl J Med 1984, 310:923-924.
164. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983, 309:453-458.
165. Fauci AS, Macher AM, Longo DL, Lane HC, Rook AH, Masur H, et al. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med 1984, 100:92-106.
166. Shearer GM Allogeneic leukocytes as a possible factor in induction of AIDS in homosexual men. N Engl J Med 1983, 308:223-224.
167. Moll B, Emeson EE, Butkus Small C, Friedland GH, Klein RS, Spigland I Inverted ratio of inducer to suppressor T-lymphocyte subsets in drug abusers with opportunistic infections. Clin Immunol Immunopathol 1982, 25:417-423.
168. Goedert JJ, Sarngadharan MG, Biggar RJ, Weiss SH, Winn DM, Grossman RJ, et al. Determinants of retrovirus (HTLV-III) antibody and immunodeficiency conditions in homosexual men. Lancet 1984, ii:711-716.
169. Melbye M, Biggar RJ, Ebbesen P, Samgadharan MG, Weiss SH, Gallo RC, et al. Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, tranmission, and disease outcome. Brit Med J 1984, 289:573-575.
170. Eyster ME, Goedert JJ, Samgadharan MG, Weiss SH, Gallo RC, Blattner WA Development and early natural history of HTLV-III antibodies in persons with hemophilia. JAMA 1985, 253:2219-2223.
171. Dobozin BS, Judson FN, Cohn DL, Penley K, Richmann PE, Blaser MJ, et al. The relationship of cellular immunity to antibodies to HTLV-III in homosexual men. Cell Immunol 1986, 98:156-171.
172. Shine D, Moll B, Emeson E, Spigland I, Harris C, Small CB, et al. Serologic, immunologic, and clinical features of parenteral drug users from contrasting populations. Am J Drug Alcohol Abuse 1987, 13:401-412.
173. Horsburgh CR, Davis KC, Hasiba U, Weiss SH, Goedert JJ, Sarin PS, et al. Altered immunity in hemophilia correlates with the presence of antibody to human T-cell lymphotropic virus type III (HTL-III). J Clin Immunol 1986, 6:37-42.
174. Fuchs D, Unterweger B, Hausen A, Reibnegger G, Werner ER, Hengster P, et al. Anti-HIV-1 antibodies, anti-HTLV-I antibodies and neopterin levels in parenteral drug addicts in the Austrian Tyrol. J Acquir Immune Defic Syndr Hum Retrovirol 1988, 1:65-66.
175. Reibnegger G, Spira TJ, Fuchs D, Werner-Felmayer G, Dierich MP, Wachter H Individual probability for onset of full-blown disease in patients infected with human immunodeficiency virus type 1. Clin Chem 1991, 37:351-355.
176. Shearer GM, Clerici M Early T-helper cell defects in HIV infection. AIDS 1991, 5:245-253.
177. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985, 313:79-84.
178. Pahwa S, Pahwa R, Saxinger C, Gallo RC, Good RA Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. Proc Natl Acad Sci USA 1985, 82:8198-8202.
179. Clerici M, Shearer GM A T H1 → TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993, 14:107-111.
180. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Mann DL, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature 1989, 339:383-385.
181. Lucey DR, Melcher GP, Hendrix CW, Zajac RA, Goetz DW, Butzin CA, et al. Human immunodeficiency virus infection in the U.S. Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis 1991, 164:631-637.
182. Berzofsky JA, Bensussan A, Cease KB, Bourges JF, Cheynier R, Lurhuma Z, et al. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 1988, 334:706-709.
183. Clerici M, Stocks NI, Zajac RA, Boswell RN, Lucey DR, Via CS, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virusseropositive patients: Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989, 84:1892-1899.
184. Clerici M, Lucey DR, Zajac RA, Boswell RN, Gebel HM, Takahashi H, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 1992, 146:2214-2219.
185. Salk J, Bretscher PA, Salk PL, Clerici M, Shearer GM A strategy for prophylactic vaccination against HIV. Science 1993, 260:1270-1272.
186. Clerici M, Clark EA, Polacino P, Axberg I, Kuller L, Casey NI, et al. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS 1994, 8:1391-1395.
187. Clerici M, Berzofsky JA, Shearer GM, Tacket CO Exposure to human immunodeficiency virus type 1 - specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis 1991, 164:178-182.
188. Beretta A, Weiss SH, Rappocciolo G, Mayur R, DeSantis C, Quirinale J, et al. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. J Infect Dis 1996, 173(2):472-476.
189. Clerici M, Giorgi JV, Chou C-C, Gudeman VK, Zack JA, Gupta P, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992, 165:1012-1019.
190. Weiss SH, Clerici M, Epstein J, Hewlett IK, Henrard DR, Palumbo PE, et al. Laboratory developments concerning virologic and immunologic detection of human retroviruses. American Public Health Association Annual Meeting 1992, 120:128. (November 11), (Session 2168).
191. Clerici M, Sison AV, Berzofsky JA, Rakusan TA, Brandt CD, Ellaurie M, et al. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS 1993, 7:1427-1433.
192. Weiss SH, Clerici M, Hewlett I, Mayur RK, Berzofsky JA, Shearer GM Evidence of immunologic and virologic responses to HIV exposure among a high risk but long-term HIV antibody seronegative (HIV-) cohort of injection drug users (IDU). IXth International Conference on AIDS 1993, I:31.
193. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994, 271(1):42-46.
194. Clerici M, Berzofsky JA, Shearer GM, Tacket CO T-helper cell assays detect exposure to HIV-1 antigen earlier than demonstration of infection by serum antibodies or polymerase chain reaction. Seventh International Conference on AIDS 1991, 2:42.
195. Weiss SH, Saxinger WC, Rechtman D, Grieco MH, Nadler J, Holman S, et al. HTLV-III infection among health care workers. Association with needle-stick injuries. JAMA 1985, 254:2089-2093.
196. Moss A, Osmond D, Bacchetti P, Gerberding J, Levy J, Carlson J, et al. Risk of seroconversion for acquired immunodeficiency syndrome (AIDS) in San Francisco health workers. J Occup Med 1986, 28:821-824.
197. Weiss SH HIV infection and the healthcare worker. Med Clin North Am 1992, 76:269-280.
198. Harper ME, Marselle LM, Gallo RC, Wong-Staal F Detection of HTLV-III-infected lymphocytes in lymph nodes and peripheral blood from AIDS patients by in situ hybridization. Proc Natl Acad Sci USA 1986, 83:772-776.
199. Chayt KJ, Harper ME, Marselle LM, Lewin EB, Rose RM, Oleske JM, et al. Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA 1986, 256:2356-2359.
200. Stoler MH, Eskin TA, Benn S, Angerer RC, Angerer LM Human T-cell lymphotropic virus type III infection of the central nervous system: a preliminary in situ analysis. JAMA 1986, 256:2360-2364.
201. Saxinger WC, Rose A Workshop on "Experience with HTLV-III antibody testing" 1985, FDA/NIH/CDC July 31, Update on: screening, laboratory and epidemiologic correlations.
202. Paul DA, Falk LA Detection of HTLV-III antigens in serum. J Cell Biochem 1986, 10A:224. Suppl.
203. Falk L, Paul D, Knigge M Detection of HTLV-III antigens in lysates of peripheral blood/lymph node mononuclear cells. J Cell Biochem 1986, 10A:200. Suppl.
204. Hedenskog M, Ward B, Dewhurst S, et al. Testing for AIDS retrovirus (HTLV-III/LAV) antibodies and antigens by indirect immunofluorescence. J Cell Biochem 1986, 10A:201. Suppl.
205. Goudsmit J, de Wolf F, Paul DA, Epstein LG, Lange JM, Krone WJ, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986, 2:177-180.
206. Allain J-P, Laurian Y, Paul DA, Senn D Serologic markers in early stages of human immunodeficiency virus infection in hemophiliacs. Lancet 1986, 2:1233-1236. Members of the AIDS-haemophilia French Study Group.
207. Phillips AN, Lee CA, Elford J, Webster A, Janossy G, Griffiths PD, et al. p24 antigenaemia, CD4 lymphocyte counts and the development of AIDS. AIDS 1991, 5:1217-1222.
208. Graziosi C, Pantaleo G, Butini L, Demarest JF, Saag MS, Shaw GM, et al. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. Proc Natl Acad Sci USA 1993, 90:6405-6409.
209. Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
210. Portegies P, Cornelissen M, Hintzen RQ, Godfried M, Bakker M, Goudsmit J Role of direct and indirect effects of HIV-1 expression and replication in the pathogenesis of AIDS dementia complex. International Conference on AIDS 1993, 9:61.
211. Chiewsilp P, Isarangkura P, Poonkasem A, Iamsilp W, Khamenketkran M, Stabunswadigan S Risk of transmission of HIV by seronegative blood. Lancet 1991, 338:1341.
212. Isarangkura P, Chiewsilp P, Tanprasert S, Nuchprayoon C Transmission of HIV infection by seronegative blood in Thailand. J Med Assoc Thai 1993, 76(Suppl. 2):106-113.
213. Tyler PE China concedes blood serum contained AIDS virus. N Y Times 1996, A3. October 25.
214. Busch MP, Taylor PE, Lenes BA, Kleinman SH, Stuart M, Stevens CE, et al. Screening of selected male blood donors for p24 antigen of human immunodeficiency virus type 1. N Engl J Med 1990, 323:1308-1312.
215. Busch MP, Mosley JW, Alter HJ, Epstein JS Case of HIV-1 transmission by antigen-positive, antibody-negative blood. N Engl J Med 1991, 325:1175.
216. Vyas GN, Rawal BD, Busch MP The risk of HIV transmission by screened blood. N Engl J Med 1996, 334(15):992.
217. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ The Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334(26):1685-1690.
218. Busch MP, Retrovirus Epidemiology Donors Study (REDS) Risques residuels de transmission virale par transfusion et estimation de l'impact de tests supplementaires de depistage. TCB 1996, 1:7-11.
219. Henrard DR, Mehaffey WF, Allain J-P A sensitive viral capture assay for detection of plasma viremia in HIV-infected individuals. AIDS Res Hum Retroviruses 1992, 8:47-52.
220. Rolon N, Hill T, Kissinger R, Sito A, Geltosky J, Britz J HIV recombinant antigen neutralization assay: a supplemental test to elisa and western blot 1987, Ortho Diagnostic Systems Inc., Raritan, NJ.
221. Muul LM Current status of polymerase chain reaction assays in clinical research of human immunodeficiency virus infection. AIDS updates 1990, 1-19. J. B. Lippincott Company, Philadelphia, PA. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
222. Schochetman G, Sninsky JJ Direct detection of human immunodeficiency virus infection using the polymerase chain reaction. AIDS testing: methodology and management issues 1991, 90-110. Springer-Verlag New York, Inc., New York, NY. G. Schochetman, J.R. George (Eds.).
223. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, et al. HIV viral load markers in clinical practice. Nature Med 1996, 2(6):625-629.
224. O'Brien WA, Hartigan PH, Martin D, Esinhart J, Hill A, Benoit S, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and risk of progression to AIDS. N Engl J Med 1996, 334(7):426-431.
225. Ioannidis JPA, Cappelleri JC Viral load and response to treatment of HIV. N Engl J Med 1996, 334(25):1671.
226. Dianzani F, Antonelli G, Riva E, Uccini S, Visco G Plasma HIV viremia and viral load in lymph nodes. Nature Med 1996, 2(8):832-833.
227. McDonough SH, Giachetti C, Yang Y, Kolk DP, Billyard E, Mimms L High throughput assay for the simultaneous or separate detection of human immunodeficiency virus (HIV) and hepatitis type C virus (HCV). Infusionsther Transfusionsmed 1998, 25:164-169.
228. Giachetti C, Linnen JM, Kolk DP, Dockter J, Gilotte-Taylor K, Park M, et al. Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA. J Clin Microbiol 2002, 40(7):2408-2419.
229. Van Gemen B, Kievits T, Nara P, Huisman HG, Jurriaans S, Goudsmit J, et al. Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 1993, 7(Suppl. 2):S107-S110.
230. Erice A, Brambilla D, Bremer J, Jackson JB, Kikka R, Yen-Lieberman B Performance characteristics of the QUANTIPLEX HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2000, 38:2837-2845.
231. Bushman FD Tethering human immunodeficiency virus 1 integrase to a DNA site directs integration to nearby sequences. Proc Natl Acad Sci USA 1994, 91:9233-9237.
232. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol 1991, 29:676-679.
233. Candotti D, Jung M, Kerouedan D, Rosenheim M, Gentilini M, M'Pele P, et al. Genetic variability affects the detection of HIV by polymerase chain reaction. AIDS 1991, 5:1003-1007.
234. Kwok S, Higuchi R Avoiding false positives with PCR. Nature 1989, 339:237-238.
235. McCreedy BJ, Chimera JA, Callaway TH Detection of HIV in clinical samples using polymerase chain reaction amplification. Abstracts of the 119th Annual Meeting of the American Public Health Association 1991, 119:302.
236. Luce MC, McCreedy BJ, Chimera JA Polymerase chain reaction amplification for the detection of human immunodeficiency virus. Infections in Medicine 1991, 8:50-55.
237. Findlay JB, Atwood SM, Bergmeyer L, Chemelli J, Christy K, Cummins T, et al. Automated closed-vessel system for in vitro diagnostics based on polymerase chain reaction. Clin Chem 1993, 39:1927-1933.
238. Heredia A, Soriano V, Weiss SH, Bravo R, Vallejo A, Denny TN, et al. Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. Clinical and Diagnostic Virology 1996, 7:85-92.
239. Zimmermann K, Schogl D, Plaimauer B, Mannhalter JW Quantitative multiple competitive PCR of HIV-1 DNA in a single reaction tube. BioTechniques 1996, 21:480-484.
240. Vener T, Axelsson M, Albert J, Uhlen M, Lundeberg J Quantification of HIV-1 using multiple competitors in single- tube assay. BioTechniques 1996, 21(2):248-255.
241. Kopko PM, Fernando LP, Bonney EN, Freeman JL, Holland PV HIV transmissions from a window-period platelet donation. Am J Clin Pathol 2001, 116(4):562-566.
242. FDA Office of Public Affairs. FDA approves first nucleic acid test (NAT) system to screen whole blood donors for infections with human immunodeficiency virus (HIV) and hepatitis C virus (HCV). FDA Talk Paper, 1-2. 2-28-2002.
243. Horsburgh CR, Ou C-Y, Jason J, Holmberg SD, Lifson AR, Moore JL, et al. Concordance of polymerase chain reaction with human immunodeficiency virus antibody detection. J Infect Dis 1990, 162:542-545.
244. Lifson AR, Stanley M, Pane J, O'Malley PM, Wilber JC, Stanley A, et al. Detection of human immunodeficiency virus DNA using polymerase chain reaction in a well-characterized group of homosexual and bisexual men. J Infect Dis 1990, 161:436-439.
245. Hsia K, Spector SA Human immunodeficiency virus DNA is present in a high percentage of CD4+ lymphocytes of seropositive individuals. J Infect Dis 1991, 164:470-475.
246. Shoebridge GI, Barone L, Wing-Simpson A, Bennetts BH, Nightingale BN, Hensley WJ, et al. Assessment of HIV status using the polymerase chain reaction in antibody-positive patients and high-risk antibody-negative haemophiliacs. AIDS 1991, 5:221-224.
247. McElrath MJ, Steinman RM, Cohn ZA Latent HIV-1 infection in enriched populations of blood monocytes and T cells from seropositive patients. J Clin Invest 1991, 87:27-30.
248. Mermin JH, Holodniy M, Katzenstein DA, Merigan TC Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis 1991, 164:769-772.
249. Shaunak S, Albright RE, Bartlett JA Amplification of human immunodeficiency virus provirus from cerebrospinal fluid: results of long-term clinical follow-up. J Infect Dis 1991, 164:818.
250. Santa G, Schneider C RNA extracted from paraffin-embedded human tissues is amenable to analysis by PCR amplification. BioTechniques 1991, 11:304-308.
251. Schechter MT, Neumann PW, Weaver MS, Montaner JSG, Cassol SA, Le TN, et al. Low HIV-1 proviral DNA burden detected by negative polymerase chain reaction in seropositive individuals correlates with slower disease progression. AIDS 1991, 5:373-379.
252. Rogers MF, Ou C-Y, Rayfield M, Thomas PA, Schoenbaum EE, Abrams E, et al. Use of the polymerase chain reaction for early detection of the proviral sequences of human immunodeficiency virus in infants born to seropositive mothers. N Engl J Med 1989, 320:1649-1654.
253. Tudor-Williams G Early diagnosis of vertically acquired HIV-1 infection. AIDS 1991, 5:103-105.
254. Gupta P, Brady M, Raab M, Urbach A Detection of human immunodeficiency virus by virus culture and polymerase chain reaction in children born to seropositive mothers. J Acquir Immune Defic Syndr Hum Retrovirol 1991, 4:1004-1006.
255. Young KKY, Nelson RP, Good RA Discordant human immunodeficiency virus infection in dizygotic twins detected by polymerase chain reaction. Ped Infect Dis J 1990, 9:454-456.
256. De Rossi A, Ades AE, Mammano F, Del Mistro A, Amadori A, Giaquinto C, et al. Antigen detection, virus culture, polymerase chain reaction, and in vitro antibody production in the diagnosis of vertically transmitted HIV-1 infection. AIDS 1991, 5:15-20.
257. Scarlatti G, Lombardi V, Plebani A, Principi N, Vegni C, Ferraris G, et al. Polymerase chain reaction, virus isolation and antigen assay in HIV-1-antibody-positive mothers and their children. AIDS 1991, 5:1173-1178.
258. Scarlatti G Paediatric HIV infection. Lancet 1996, 348(9031):863-868.
259. Wormser GP, Joline C, Bittker S, Forseter G, Kwok S, Sninsky JJ Polymerase chain reaction for seronegative health care workers with parenteral exposure to HIV-infected patients. N Engl J Med 1989, 321:1681-1682.
260. Raffanti S, Svenningsson A, Resnick L Determination of HIV-1 status of discarded sharps: polymerase chain reaction using minute quantities of blood. JAMA 1990, 264:2501.
261. Busch MP, Eble BE, Khayam-Bashi H, Heilbron D, Murphy EL, Kwok S, et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med 1991, 325:1-5.
262. Murthy KK, Henrard DR, Eichberg JW, Cobb KE, Busch MP, Allain JP, et al. Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion 1999, 39(7):688-693.
263. Imagawa DT, Lee MH, Visscher B, Dudley J, Detels R Human immunodeficiency virus type 1 infection in homosexual men who remain seronegative for prolonged periods. N Engl J Med 1989, 321:1681.
264. Imagawa D, Detels R HIV-1 in seronegative homosexual men. N Engl J Med 1991, 325:1250-1251.
265. Hewlett IK, Laurian Y, Epstein J, Hawthorne CA, Ruta M, Allain J-P Assessment by gene amplification and serological markers of transmission of HIV-1 from hemophiliacs to their sexual partners and secondarily to their children. J Acquir Immune Defic Syndr Hum Retrovirol 1990, 3:714-720.
266. Lefrère JJ, Moriotti M, Ferrer-Le-Coeur F, Rouger P, Noel B, Bosser C PCR testiing in HIV-1 seronegative haemophilia. Lancet 1990, 336:1386.
267. Mariotti M, Lefrère JJ, Noel B, Ferrer-Le-Coeur F, Vittecoq D, Girot R, et al. DNA amplification of HIV-1 in seropositive individuals and in seronegative at-risk individuals. AIDS 1990, 4:633-637.
268. Shoebridge GI, Gatenby PA, Nightingale BN, Barone L, Wing-Simpson A, Bennetts BH, et al. Polymerase chain reaction testing of HIV-1 seronegative at-risk individuals. Lancet 1990, 336:180-181.
269. Wormser GP, Rabkin CS, Joline C Frequency of nosocomial transmission of HIV infection among health care workers. N Engl J Med 1988, 319:307-308.
270. Hooper C Eavesdropping on rare 'silent' HIV-1 infection. J NIH Research 1991, 3:71-76.
271. Lee T-H, El-Amad Z, Reis M, Adams M, Donegan EA, O'Brien TR, et al. Absence of HIV-1 DNA in high-risk seronegative individuals using high-input polymerase chain reaction. AIDS 1991, 5:1201-1207.
272. Nielsen C, Teglbjaerg LS, Pedersen C, Lundgren JD, Nielsen CM, Vestergaard BF Prevalence of HIV infection in seronegative high-risk individuals examined by virus isolation and PCR. J Acquir Immune Defic Syndr Hum Retrovirol 1991, 4:1107-1111.
273. Sheppard HW, Dondero D, Arnon J, Winkelstein W An evaluation of the polymerase chain reaction in HIV-1 seronegative men. J Acquir Immune Defic Syndr Hum Retrovirol 1991, 4:819-823.
274. Ensoli F, Fiorelli V, Mezzaroma I, D'Offizi G, Rainaldi L, Luzi G, et al. Plasma viraemia in seronegative HIV-1-infected individuals. AIDS 1991, 5:1195-1199.
275. Jason J, Ou C-Y, Moore JL, Lawrence DN, Schochetman G, Evatt BL, et al. Prevalence of human immunodeficiency virus type 1 DNA in hemophilic men and their sex partners. J Infect Dis 1989, 160:789-794.
276. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002, 16(8):1119-1129.
277. Holodniy M, Katzenstein DA, Sengupta S, Wang AM, Casipit C, Schwartz DH, et al. Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991, 163:862-866.
278. Hall WW, Liu CR, Schneewind O, Takahashi H, Kaplan MH, Roupe G, et al. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science 1991, 253:317-320.
279. Agius G, Kolesnitchenko V, Snart R, Zagury JF, Laaroubi K, Zagury D Variable stringency hybridization of polymerase chain reaction amplified HIV-1 DNA fragments. J Virol Methods 1990, 30:141-150.
280. Villinger F, Powell JD, Jehuda-Cohen T, Neckelmann N, Vuchetich M, De B, et al. Detection of occult simian immunodeficiency virus SIVsmm infection in asymptomatic seronegative nonhuman primates and evidence for variation in SIV gag sequence between in vivo- and in vitro-propagated virus. J Virol 1991, 65:1855-1862.
281. McNeary T, Westervelt P, Thielan BJ, Trowbridge DB, Garcia J, Whittier R, et al. Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type I isolates from individuals involved in a clustered infectious outbreak. Proc Natl Acad Sci USA 1990, 87:1917-1921.
282. CDC Possible transmission of human immunodeficiency virus to a patient during an invasive dental procedure. MMWR 1990, 39:489-492.
283. Kleim JP, Ackermann A, Brackmann HH, Gahr M, Schneweis KE Epidemiologically closely related viruses from hemophilia B patients display high homology in two hypervariable regions of the HIV-1 env gene. AIDS Res Hum Retroviruses 1991, 7:417-421.
284. Cichutek K, Norley S, Linde R, Kreuz W, Gahr M, Lower J, et al. Lack of HIV-1 V3 region sequence diversity in two haemophiliac patients infected with a putative biologic clone of HIV-1. AIDS 1991, 5:1185-1187.
285. Koup RA, Ho DD Immunosilent HIV-1 infection: intrigue continues. AIDS 1991, 5:1263.
286. Louwagie J, McCutchan FE, Peeters M, Brennan TP, Sanders-Buell E, Eddy GA, et al. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes. AIDS 1993, 7(6):769-780.
287. Myers G, Korber BTM, Berzofsky JA, Smith RF, Pavlakis GN Human Retroviruses and AIDS: A compilation and analysis of nucleic acid and amino acid sequences 1992, Los Alamos National Laboratory, Los Alamos.
288. Myers G Tenth anniversary perspectives on AIDS. HIV: between past and future. AIDS Res Hum Retroviruses 1994, 10(11):1317-1324.
289. WHO Network for HIV Isolation and Characterization HIV type 1 variation in World Health Organization-sponsored vaccine evaluation sites: genetic screening, sequence analysis, and preliminary biological characterization of selected viral strains. AIDS Res Hum Retroviruses 1994, 10:1327-1343.
290. Bachmann MH, Delwart EL, Shpaer EG, Lingenfelter P, Singal R, Mullins JI Rapid genetic characterization of HIV type 1 strains from four World Health Organization-sponsored vaccine evaluation sites using a heteroduplex mobility assay. WHO Network for HIV Isolation and Characterization. AIDS Res Hum Retroviruses 1994, 10:1345-1353.
291. Kuiken CL, Zwart G, Baan E, Coutinho RA, van den Hoek JA, Goudsmit J Increasing antigenic and genetic diversity of the V3 variable domain of the human immunodeficiency virus envelope protein in the course of the AIDS epidemic. Proc Natl Acad Sci USA 1993, 90:9061-9065.
292. Lange JM, Teeuwsen VJ, Boucher CA, Vahlne A, Barin F, Tjong-A-Hung S, et al. Antigenic variation of the dominant gp41 epitope in Africa. AIDS 1993, 7:461-466.
293. Dietrich U, Grez M, Von Briesen H, Panhans B, Geissendörfer M, Kühnel H, et al. HIV-1 strains from India are highly divergent from prototypic African and U.S./European strains, but are linked to a South African isolate. AIDS 1993, 7:23-27.
294. Kalish ML, Baldwin A, Raktham S, Wasi C, Luo C-C, Schochetman G, et al. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials. AIDS 1995, 9(8):851-857.
295. Wolinsky SM, Wike CM, Korber BTM, Hutto C, Parks WP, Rosenblum LL, et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science 1992, 255:1134-1137.
296. Wolfs TFW, Zwart G, Bakker M, Valk M, Kuiken CL, Goudsmit J Naturally occurring mutations within HIV-1 V3 genomic RNA lead to antigenic variation dependent on a single amino acid substitution. Virology 1991, 185:195-205.
297. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993, 261:1179-1181.
298. Reitz MS, Hall L, Robert-Guroff M, Lautenberger J, Hahn BM, Shaw GM, et al. Viral variability and serum antibody response in a laboratory worker infected with HIV type 1 (HTLV type IIIB). AIDS Res Hum Retroviruses 1994, 10(9):1143-1155.
299. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Leigh Brown AJ, Simmonds P Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol 1993, 67(6):3345-3356.
300. Balfe P, Simmonds P, Ludlam CA, Bishop JO, Leigh Brown AJ Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source: rate of sequence change and low frequency of inactivating mutations. J Virol 1990, 64:5233-6221.
301. Weiss SH, Goedert JJ, Gartner S, Popovic M, Waters DJ, Markham PD, et al. Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science 1988, 239:68-71.
302. Diaz RS, Sabino EC, Mayer A, Mosley JW, Busch MP Dual human immunodeficiency virus type 1 infection and recombination in a dually exposed transfusion recipient. J Virol 1995, 69:3273-3281. Transfusion Safety Study Group.
303. DeBry RW, Abele LG, Weiss SH, Hill MD, Bouzas M, Lorenzo E, et al. Dental HIV transmission?. Nature 1993, 361:691.
304. Wain-Hobson S The fastest genome evolution ever described: HIV variation in situ. Curr Opin Genet Dev 1993, 3:878-883.
305. Ezzell C Recombination between HIV-1 clades not so rare. J NIH Research 1995, 7:24-26.
306. Vartanian J-P, Meyerhans A, Asjo B, Wain-Hobson S Selection, recombination, and G> A hypermutation of human immunodeficiency virus type 1 genomes. J Virol 1991, 65:1779-1788.
307. Zhu T, Wang N, Carr A, Wolinsky S, Ho DD Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor. J Virol 1995, 69:1324-1327.
308. Salahuddin SZ, Markham PD, Popovic M, Sarngadharan MG, Omdorff S, Fladagar A, et al. Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources. Proc Natl Acad Sci USA 1985, 82:5530-5534.
309. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986, 233:215-219.
310. Gartner S, Markovits P, Markovitz DM, Betts RF, Popovic M Virus isolation from and identification of HTLV-III/LAV-producing cells in brain tissue from a patient with AIDS. JAMA 1986, 256:2365-2371.
311. Streicher HZ, Joynt RJ HTLV-III/LAV and the monocyte/macrophage. JAMA 1986, 256:2390-2391.
312. Jackson JB, Coombs RW, Sannerud K, Rhame FS, Balfour HH Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol 1988, 26:1416-1418.
313. Weiss R Hot prospect for new gene amplifier. Ligase chain reaction, a combination DNA amplifier and genetic screen, could do for DNA diagnostics what PCR has done for basic molecular biology. Science 1991, 254:1272-1273.
314. Barany F Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc Natl Acad Sci USA 1991, 88:189-193.
315. Ii S, Minnerath S, Ii K, Dyck PJ, Sommer S Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations. Neurology 1991, 41:893-898.
316. Busch M, Schumacher RT, Stramer S, Garrett PE Consistent sequential detection of RNA, antigen and antibody in early HIV infection: assessment of the window period. XI International Conference on AIDS 1996, 1:219.
317. Busch MP HIV and blood transfusion: focus on seroconversion. Vox Sang 1994, 67(Suppl 3):13-18.
318. Busch MP, Kleinman SH Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases. Transfusion 2000, 40:143-159.
319. Busch MP, Lee LLL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995, 35:91-97.
320. Busch MP, Satten GA, Herman SA, Henrard DR, Sakahara NS, Garrett PE, et al. Time course and kinetics of HIV viremia during primary infection. Transfusion 1996, 36:41S. (Suppl), (Abstract #S164).
321. Petersen LR, Satten GA, Dodd RY, Busch M, Kleinman S, Grindon A, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994, 34:283-289.
322. Horsburgh CR, Ou C-Y, Jason J, Holmberg SD, Longini IM, Schable C, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet 1989, ii:637-640.
323. Meyohas MC, Morand-Joubert L, Van de Wiel P, Mariotti M, Lefrère JJ Time to HIV seroconversion after needlestick injury. Lancet 1995, 345:1634-1635.
324. Moyle G, Baog FC, Barton SE Case report: missed human immunodeficiency virus seroconversion. Int J STD AIDS 1992, 3:364-365.
325. Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, Barnes TG, et al. Acute AIDS retrovirus infection: definition of a clinical illness associated with seroconversion. Lancet 1985, i:537-540.
326. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with the human immunodeficiency virus infection. Arch Intern Med 1988, 148:945-949.
327. van Hintzenstem J, Jahn G, Mang K, Harms D, Fleckenstein B Delayed seroconversion to HIV in a hemophiliac. Klin Wochenschr 1988, 66(9):410-411.
328. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, minna JD, Gallo RC Detection and isolation of type-C retrovirus particles from fresh and cultured lymphocytes of patients with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980, 77:7415-7419.
329. Blattner WA Human retrovirology: HTLV 1990, Raven Press, New York.
330. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Blayney D, Golde D, et al. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982, 218:571-573.
331. Hahn BH, Popovic M, Kalyanaraman VS, Shaw GM, LoMonico A, Weiss SH, et al. Detection and characterization of an HTLV-II provirus in a patient with AIDS. Acquired immune deficiency syndrome 1984, 73-81. Alan R. Liss, Inc., New York, NY.
332. de Thé G, Bomford R, Kazanji M, Ibrahim F Human T cell lymphotropic virus: necessity for and feasibility of a vaccine. Ciba Foundation Symposium 1994, 187:47-55.
333. Robert-Guroff M, Weiss SH, Giron JA, Jennings AM, Ginzburg HM, Margolis IB, et al. Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region. JAMA 1986, 255:3133-3137.
334. Weiss SH, Ginzburg HM, Saxinger WC, Cantor KP, Mundon FK, Zimmerman DH, et al. Emerging high rates of human T-cell lymphotropic virus type I (HTLV-I) and HIV infection among U.S. drug abusers (DA). 3rd International Conference on AIDS 1987, 211.
335. Palumbo PE, Weiss SH, McCreedy BJ, Alexander SS, Denny TN, Klein CW, et al. Evaluation of human T cell lymphotropic virus infection in a cohort of injecting drug users. J Infect Dis 1992, 166:889-896.
336. Caussy D, Weiss SH, Blattner WA, Goedert JJ, French J, Altman R Risk factors for HTLV seropositivity among intravenous drug abusers from New Jersey. Fourth Annual Retrovirology Conference 1991.
337. Gore I, Snyder TL, Decker WD, Hahn BH, Parks ES, Weiss SH, Shorty VJ, Parks WP, Blattner WA, Shaw G Frequent isolation and molecular identification of human T-cell leukemia virus type-2 (HTLV-2) in three U.S. population centers. Fifth International Conference on AIDS 1989, 638.
338. Lee HH, Weiss SH, Brown LS, Mildvan D, Shorty VJ, Saravolatz L, et al. Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA. J Infect Dis 1990, 162:347-352.
339. Briggs NC, Battjes RJ, Cantor KP, Blattner WA, Yellin FM, Wilson S, et al. Seroprevalence of human T cell lymphotropic virus type II infection, with or without human immunodeficiency type 1 coinfection, among U.S. intravenous drug users. J Infect Dis 1995, 172:51-58.
340. Schreiber GB, Murphy EL, Horton JA, Wright DJ, Garfein R, Co Chien HT, et al. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: the Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14(3):263-271.
341. Gallo RC, Kalyanaraman VS, Sarngadharan MG, Sliski A, Vonderheid EC, Maeda M, et al. Association of the human type C retrovirus with a subset of adult T-cell cancers. Cancer Res 1983, 43:3892-3899.
342. Blattner WA, Blayney DW, Jaffe ES, Robert-Guroff M, Kalyanaraman VS, Gallo RC Epidemiology of HTLV-associated leukemia. Haematol Blood Transf 1983, 28:148-155.
343. Blattner WA Human T-lymphotrophic viruses and diseases of long latency. Ann Intern Med 1989, 111:4-6.
344. Clark JW, Gurgo C, Franchini G, Gibbs WN, Lofters W, Neuland C, et al. Molecular epidemiology of HTLV-I-associated non-Hodgkin's lymphomas in Jamaica. Cancer 1988, 61:1477-1482.
345. Uchiyama T Adult T-cell leukemia. Blood Rev 1988, 2:232-238.
346. Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, et al. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 1989, 43:250-253.
347. Wiktor SZ, Jacobson S, Weiss SH, Shaw GM, Reuben JS, Shorty VJ, et al. Spontaneous lymphocyte proliferation in HTLV-II infection. Lancet 1991, 337:327-328.
348. Kramer A, Jacobson S, Reuben JF, Murphy EL, Wikor SZ, Cranston B, et al. Spontaneous lymphocyte proliferation in symptom-free HTLV-I positive Jamaicans. Lancet 1989, 2:923-924.
349. Prince HE, York J, Owen SM, Lal RB Spontaneous proliferation of memory (CD45RO+) and naive (CD45RO-) subsets of CD4 cells and CD8 cells in human T lymphotropic virus (HTLV) infection: distinctive patterns for HTLV-I versus HTLV-II. Clin Exper Immunol 1995, 102:256-261.
350. Weiss SH, Clerici M, Mayur RK, Denny TN, Quirinale JE, Berzofsky JA, et al. Impact of HTLV-II infection upon cellular immunologic response to HIV exposure in HIV seronegative drug users. AIDS Research and Human Retroviruses 1994, 10:444. (4).
351. Weiss SH The evolving epidemiology of human T lymphotropic virus type II. J Infect Dis 1994, 169:1080-1083.
352. Goedert JJ, Battjes RJ No excess mortality with HTLV-II. Eighth International Conference on Human Retrovirology: HTLV 1997, ED26. June 9-13.
353. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels RJ Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001, 15(10):1295-1302.
354. Hjelle B, Appenzeller O, Mills R, Alexander S, Torrez-Martinez N, Jahnke R, et al. Chronic neurodegenerative disease associated with HTLV-II infection. Lancet 1992, 339:645-646.
355. Modahl LE, Young KC, Varney KF, Khayam-Bashi H, Murphy EL Are HTLV-II-seropositive injection drug users at increased risk of bacterial pneumonia, abscess, and lymphadenopathy?. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16(3):169-175.
356. Anderson D, Epstein J, Pierik LT, Solomon J, Blattner WA, Saxinger WC, et al. Licensure of screening tests for antibody to human T-lymphotropic virus type I. MMWR 1988, 37:736-747.
357. Barnes DM HTLV-I: to test or not to test. Science 1988, 242:372-373.
358. Kline RL, Brothers T, Halsey N, Boulos R, Lairmore MD, Quinn TC Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II. Lancet 1991, 337:30-33.
359. Wiktor SZ, Pate EJ, Weiss SH, Gohd RS, Correa P, Fontham ET, et al. Sensitivity of HTLV-I antibody assays for HTLV-II. Lancet 1991, 338:512-513.
360. Hartley TM, Malone GE, Khabbaz RF, Lal RB, Kaplan JE Evaluation of a recombinant human T-cell lymphotropic virus type I (HTLV-I) p21E antibody detection enzyme immunoassay as a supplementary test in HTLV-I/II antibody testing algorithms. J Clin Microbiol 1991, 29:1125-1127.
361. Lal RB, Rudolph DL, Lairmore MD, Khabbaz RF, Garfield M, Coligan JE, et al. Serologic discrimination of human T cell lymphotropic virus infection by using a synthetic peptide-based enzyme immunoassay. J Infect Dis 1991, 163:41-46.
362. Viscidi RP, Hill PM, Li S, Cerny EH, Vlahov D, Farzadegan H, et al. Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides. J Acquir Immune Defic Syndr Hum Retrovirol 1991, 4:1190-1198.
363. Andersson A, Thortensson R, Ramirez KG, Krook A, von Sydow M, Dias F, et al. Comparative evaluation of 14 immunoassays for detection of antibodies to the human T-lymphotropic virus types I and II using panels of sera from Sweden and West Africa. Transfusion 1999, 39:845-851.
364. Weiss SH, Denny TN, Quirinale J, Mayur RK, Palumbo P, Heredia A, et al. HTLV-II screening issues: false negative HTLV ELISA results within a high risk IDU cohort. AIDS Res Hum Retroviruses 1994, 10:451. (4).
365. Gallo D, Yeh ET, Moore ES, Hanson CV Comparison of four enzyme immunoassays for detection of human T- cell lymphotropic virus type 2 antibodies. J Clin Microbiol 1996, 34(1):213-215.
366. Hinuma Y, Nagata K, Hanaoka M Adult T-cell leukemia antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 1981, 78:6476-6480.
367. Ikeda M, Fujino R, Matsui T, Yoshida T, Komoda H, Imai J A new agglutination test for serum antibodies to adult T-cell leukemia virus. Gann 1984, 75:845-848.
368. Okayama A, Ishizaki J, Tachibana N, Tsuda K, Essex M, Mueller N The particle agglutination (PA) assay and its use in detecting lower titer HTLV-I antibodies. Human Retrovirology: HTLV 1990, 401-407. Raven Press, New York. W.A. Blattner (Ed.).
369. Hartley TM, Khabbaz RF, Cannon RO, Kaplan JE, Lairmore MD Characterization of antibody reactivity to human T-cell lymphotropic virus types I and II using immunoblot and radio-immunoprecipitation assays. J Clin Microbiol 1990, 28:646-650.
370. Biggar RJ, Buskell-Bales Z, Yakshe PN, Caussy D, Gridley G, Seeff L Antibody to human retroviruses among drug users in three east coast American cities, 1972-1976. J Infect Dis 1991, 163:57-63.
371. Wiktor SZ, Alexander SS, Shaw GM, Weiss SH, Murphy EL, Wilks RJ, et al. Distinguishing between HTLV-I and HTLV-II by western blot. Lancet 1990, 335:1533.
372. Cantor KP, Weiss SH, Goedert JJ, Battjes RJ HTLV-I/II seroprevalence and HIV/HTLV coinfection among U.S. intravenous drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1991, 4:460-467.
373. Dezzutti CS, Cowan EP, Lal RB Human T-cell lymphotropic virus types I and II. The Manual of Clinical Microbiology 2003, American Society of Microbiology Press.
374. Guidelines for counseling persons infected with human t-cell lymphotroic virus type I (HLTV-I) and type II (HLTV-II). Ann Intern Med 1993, 118:448-454. CDC U.S. Public Health Service Working Group.
375. Weiss SH, Blattner WA, Ginzburg HM, Giron JA, Waddell RD, Margolis IB, et al. Retroviral antibodies in parenteral drug users (PDU) from an AIDS endemic region. Program and Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 1985, 25:228.
376. Essex M, McLane MF, Lee TH, Falk L, Howe CWS, Mullins JI, et al. Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS. Science 1983, 220:859-862.
377. Essex M, McLane MF, Lee TH, Tachibana N, Mullins JI, Dreiss J, et al. Antibodies to human T-cell leukemia virus: membrane antigens (HTLV-MA) in hemophiliacs. Science 1983, 221:1061-1064.
378. Weiss SH, Saxinger WC, Ginzburg HM, Mundon FK, Blattner WA Human T-cell lymphotropic virus type I (HTLV-I) and HIV prevalences among U.S. drug abusers. Proceedings of the American Society of Clinical Oncology 1987, 6:4.
379. Alvord WG, Drummond JE, Arthur LO, Biggar RJ, Goedert JJ, Levine PH, et al. A method for predicting individual HIV infection status in the absence of clinical information. AIDS Res Hum Retroviruses 1988, 4:295-304.
380. Weiss SH, Klein C, French J, Palumbo P, Blattner WA, Altman R Mortality associated with human T-cell lymphotropic virus type 2 (HTLV-2) infection in intravenous drug abusers. Seventh International Conference on AIDS 1991, 2:82.
381. Palumbo PE, Weiss SH, McCreedy BJ, Alexander SS, Denny TN, Klein CW, et al. Evaluation of HTLV infection in a cohort of injecting drug users. J Infect Dis 1992, 166:896-899.
382. Hjelle B, Wilson C, Cyrus S, Wiltbank T, Schammel C, Alexander S HTLV-I EIA false-negative rate: failure to detect HTLV-I and HTLV-II-positive donations. Transfusion 1992, 32:57S.
383. Soriano V, Calderon E, Gutierrez M, Tuset C, Martinez-Zapico R, Gonzalez-Lahoz J Misdiagnosis of HTLV-II infection using HTLV-I screening assays. AIDS 1993, 7(10):1395.
384. Varnier OE, Lillo F, Alexander SS, Forbis RM, Present W, Lazzarin A HTLV seroreactivity in Italian intravenous drug addicts is primarily due to HTLV-II infection. JAMA 1991, 265:597.
385. Bouzas MB, Muchinik G, Zapiola I, DeRosa MF, Bianco RP, Cahn P, et al. Human T cell lymphotropic virus type II infection in Argentina. J Infect Dis 1991, 164:1026-1027.
386. Reeves WC, Saxinger C, Brenes MM, Quiroz E, Clark JW, Hoh M-W, et al. Human T-cell lymphotropic virus type I (HTLV-I) seroepidemiology and risk factors in metropolitan Panama. Am J Epidemiol 1988, 127:532-539.
387. Lairmore MD, Jacobson S, Gracia F, De BK, Castillo L, Larreategui M, et al. Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama. Proc Natl Acad Sci USA 1990, 87:8840-8844.
388. Bianco C, Kessler D, Hall W, Rios M, Khabbaz RF, Kaplan JE Transmission of HTLV-II by HTLV-I screened blood products. American Association of Blood Banks Forty-sixth Annual Meeting 1993, 118. October 27, (Program).
389. Lipka JJ, Santiago P, Chan L, Reyes GR, Samuel KP, Blattner WA, et al. Modified western blot assay for confirmation and differentiation of human T cell lymphotropic virus type I and II. J Infect Dis 1991, 164:400-403.
390. Chen Y-M, Lee T-H, Wiktor SZ, Shaw GM, Murphy EL, Blattner WA, et al. Type-specific antigens for serological discrimination of HTLV-I and HTLV-II infection. Lancet 1990, 336:1153-1155.
391. Lillehoj EP, Alexander SS, Dubrule CJ, Wiktor S, Adams R, Tai C-C, et al. Development and evaluation of an HTLV-I serologic confirmatory assay incorporating a recombinant envelope polypeptide. J Clin Microbiol 1990, 28:2653-2658.
392. Hall WW, Kaplan MH, Salahuddin SZ, Oyaizu N, Gurgo C, Coronesi M, et al. Concomitant infections with human T-cell leukemia viruses (HTLVs) and human immunodeficiency virus (HIV): identification of HTLV-II infection in intravenous drug abusers (IVDAs). Human Retrovirology: HTLV 1990, 115-127. Raven Press, New York. W.A. Blattner (Ed.).
393. Hjelle B, Scalf R, Swenson S High frequency of human T-cell leukemia-lymphoma virus type II infection in New Mexico blood donors: determination by sequence-specific oligonucleotide hybridization. Blood 1990, 76:450-454.
394. Rosenblatt JD, Zack JA, Chen ISY, Lee H Recent advances in detection of human T-cell leukemia viruses type I and type II infection. Nat Immun Cell Growth Regul 1990, 9:143-149.
395. Chen Y-MA, Essex M Identification of a recombinant HTLV-II envelope protein for serological detection of HTLV-II carriers. AIDS Res Hum Retroviruses 1991, 7:453-457.
396. Horal P, Hall WW, Svennerholm B, Lycke J, Jeansson S, Rymo L, et al. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides. Proc Natl Acad Sci USA 1991, 88:5754-5758.
397. Lal RB, Heneine W, Rudolph DL, Present WB, Hofhienz D, Hartley TM, et al. Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals. J Clin Microbiol 1991, 29(10):2253-2258.
398. Liu H, Shah M, Stramer SL, Chen W, Weiblen BJ, Murphy EL Sensitivity and specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain reaction and several serologic assays in screening apopulation with a high prevalence of HTLV-II. Transfusion 1999, 39:1185-1193.
399. Lee H, Swanson P, Shorty VS, Zack JA, Rosenblatt JD, Chen ISY High rate of HTLV-II infection in seropositive IV drug abusers in New Orleans. Science 1989, 244:471-475.
400. Ehrlich GD, Greenberg S, Abbott MA Detection of human T-cell lymphoma/leukemia viruses. PCR protocols: a guide to methods and applications 1990, 325-336. Academic Press, Inc., San Diego, Californian. M.A. Innis, D.H. Gelfand, J.J. Sninsky, T.J. White (Eds.).
401. Kwok S, Gallo D, Hanson C, McKinney N, Poiesz B, Sninsky JJ High prevalence of HTLV-II among intravenous drug abusers: PCR confirmation and typing. AIDS Res Hum Retroviruses 1990, 6:561-565.
402. Smith D, Mann E, Anderson E, Canavaggio M, Lee H Comparison of HTLV-I/II infection by serology & PCR. Seventh International Conference on AIDS 1991, 1:29.
403. De BK, Srinivasan A Multiple primer pairs for the detection of HTLV-I by PCR. Nucleic Acids Res 1989, 17:2142.
404. Eiraku N, Monken C, Kubo T, Zhu SW, Rios M, Bianco C, et al. Nucleotide sequence and restriction fragment length polymorphism analysis of the long terminal repeat of human T cell leukemia virus type II. AIDS Res Hum Retroviruses 1995, 11(5):625-636.
405. Hall WW, Kubo T, Ijichi S, Zhu SW Human T cell leukemia/lymphoma virus, type II (HTLV-II). Semin Virol 1994, 1-34. April.
406. Hjelle B, Zhu SW, Takahaski H, Ijichi S, Hall WW Endemic human T cell leukemia virus type II infection in southwestern U.S. indians involves two prototype variants of virus. J Infect Dis 1993, 168:737-740.
407. Ijichi S, Tajima K, Zaninovic V, Leon FE, Katahira Y, Sonoda S, et al. Identification of human t cell leukemia virus type IIb infection in the Wayu, an aboriginal population of Colombia. Jpn J Cancer Res 1993, 84:1215-1218.
408. Ijichi S, Tajima K, Zaninovic V, Leon FE, Katahira Y, Sonoda S, et al. Identification of human t cell leukemia virus type IIb infection in the Wayu, an aboriginal population of Colombia. Jpn J Cancer Res 1993, 85:441. Erratum.
409. Busch MP, Switzer WM, Murphy EL, Thomson R, Heneine W Absence of evidence of infection with divergent primate T-lymphotropic viruses in United States blood donors who have seroindeterminate HTLV test results. Transfusion 2000, 40(4):443-449.
410. Hall WW, Takahashi H, Lui C, Kaplan MH, Scheewind O, Ijichi S, et al. Multiple isolates and characteristics of human T-cell leukemia virus type II. J Virol 1992, 66:2456-2463.
411. Takahashi H, Zhu SW, Ijichi S, Vahlne A, Suzuki H, Hall WW Nucleotide sequence analysis of human T cell leukemia virus, type II (HTLV-II) isolates. AIDS Res Hum Retroviruses 1993, 9:721-732.
412. Kobayashi N, Hatanaka M Molecular aspects of human T-cell leukemia virus type I (HTLV-I). Cancer Res 1986, 1:64-95.
413. Korber B, Okayama A, Donnelly R, Tachibana N, Essex M Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia. J Virol 1991, 65:5471-5476.
414. Khabbaz RF, Harter D, Lairmore M, Horsburgh CR, Schoenbaum EE, Roberts B, et al. Human T lymphotropic virus type II (HTLV-II) infection in a cohort of New York intravenous drug users: an old infection?. J Infect Dis 1991, 163:252-256.
415. Chen Y-MA, Okayama A, Lee T-H, Tachibana N, Mueller N, Essex M Sexual transmission of human T-cell leukemia virus type I associated with the presence of anti-Tax antibody. Proc Natl Acad Sci USA 1991, 88:1181-1186.
416. Weiss SH, French J, Holland B, Parker M, Lin-Greenberg A, Altman R HTLV-I/II co-infection is significantly associated with risk for progression to AIDS among HIV+ intravenous drug abusers. Fifth International Conference on AIDS 1989, 75.
417. DeShazo RD, Chadha N, Morgan JE, Shorty VJ, Rangan SRS, Kalyanaraman VS, et al. Immunologic assessment of a cluster of asymptomatic HTLV-I-infected individuals in New Orleans. Am J Med 1989, 86:65-70.
418. Kira J-I, Koyanagi Y, Hamakado T, Itoyama Y, Yamamoto N, Goto I HTLV-II in patients with HTLV-I-associated myelopathy. Lancet 1991, 338:64-65.
419. Kiyokawa T, Yamaguchi K, Nishimura Y, Yoshiki K, Takatsuki K Lack of anti-HTLV-II seropositivity in HTLV-I-associated myelopathy and adult T-cell leukaemia. Lancet 1991, 338:451.
420. Welles SL, Mueller N, Tachibana N, Shishime E, Okayama A, Murai K, et al. Decreased eosinophil numbers in HTLV-I carriers. Lancet 1991, 337:987.
421. Davenport A, Grant PJ False-positive autoantibodies in HIV infection. Lancet 1990, 336:317-318.
422. Agbalika F, Ferchal F, Garnier J-P, Eugene M, Bedrossian J, Lagrange PH False-positive HIV antigens related to emergence of a 25-30 kD protein detected in organ recipients. AIDS 1992, 6:959-962.
423. Food and Drug Administration Open meeting transcript of the Vaccine and Related Biologic Products Advisory Committee of the Food and Drug Administration 1992, Miller Reporting Company, Inc., Bethesda, MD.
424. Food and Drug Administration Open meeting transcript of the Blood Products Advisory Committee of the Food and Drug Administration 1992, C.A.S.E.T. Associates, Ltd., Rockville.
425. MacKenzie WR, Davis JP, Peterson DE, Hibbard AJ, Becker G, Zarvan BS Multiple false-positive serologic tests for HIV, HTLV-1, and hepatitis C following influenza vaccination, 1991. JAMA 1992, 268:1015-1017.
426. Stramer SL, Dillender MJ, Pendy LM, Holzer TJ Abbott Laboratories. False positive EIA reactivity in multiple blood bank screening assays is due to non-specific binding of IgM. Transfusion 1992, 32:30S. (Suppl).
427. CDC False-positive serologic tests for human T-cell lymphotropic virus type I among blood donors following influenza vaccination, 1992. MMWR 1993, 42:173-175.
428. Consortium for Retrovirus Serology Standardization Serological diagnosis of human immunodeficiency virus infection by western blot testing. JAMA 1988, 260:674-679.
429. CDC Interpretive criteria used to report western blot results for HIV-1-antibody testing-United States. MMWR 1991, 40:692-695.
430. Gaines H, Sonnerborg A, Czajkowski J, Chiodi F, Fenyö EM, von Sydow M, et al. Antibody response in primary human immunodeficiency virus infection. Lancet 1987, i:1249-1253.
431. Ho DD, Samgadharan MG, Resnick L, DiMarzo-Veronese F, Rota TR, Hirsch MS Primary human T-lymphotropic virus type III infection. Ann Intern Med 1985, 103:880-883.